Načítá se...
Loss of BAP1 as a candidate predictive biomarker for immunotherapy of mesothelioma
As trials of immune checkpoint inhibitor (ICI) therapies demonstrate responses in only a minority of pleural mesotheliomas (PlMs) and largely exclude patients with the related peritoneal mesothelioma (PeM), clinicians need predictive biomarkers of response and inclusion of PeM patients in future tri...
Uloženo v:
| Vydáno v: | Genome Med |
|---|---|
| Hlavní autoři: | , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
BioMed Central
2019
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6436227/ https://ncbi.nlm.nih.gov/pubmed/30914057 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13073-019-0631-0 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|